Trigeminal nerve stimulation (TNS), which has been cleared in the US for treating attention-deficit/hyperactivity disorder (ADHD), is not effective in children with ...

A large multicentre clinical trial led by King’s College London with 150 children and adolescents has shown that a device cleared by the US FDA to treat ADHD is not effective in reducing symptoms. A ...

Please provide your email address to receive an email when new articles are posted on . Non-superiority of the treatments was observed at 4 weeks and again at 6 months. Adverse events among ...

In 2019, the FDA cleared an external trigeminal nerve stimulation (eTNS) device to treat ADHD symptoms in children ages 7-12 years. In contrast to earlier findings, a new trial in England suggested ...

The trial examined the short- and long-term efficacy of real vs sham TNS in 150 children and adolescents with ADHD (mean age, 12.6 years). HealthDay News — External trigeminal nerve stimulation (TNS) ...

The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their ...

(RTTNews) - NeuroOne Medical Technologies Corp. (NMTC) on Wednesday announced that it has completed its 510(k) submission to the U.S. Food and Drug Administration for its OneRF Trigeminal Nerve ...